48 related articles for article (PubMed ID: 10605305)
1. Concomitant radiochemotherapy in unresectable carcinoma of the exocrine pancreas: cost-effectiveness analysis.
Cellini N; Costamagna G; Morganti AG; Valentini V; Macchia G; Mutignani M; Pandolfi M; Trodella L
Rays; 1999; 24(3):447-52. PubMed ID: 10605305
[TBL] [Abstract][Full Text] [Related]
2. Results and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy.
Micke O; Hesselmann S; Bruns F; Horst E; Devries A; Schüller P; Willich N; Schäfer U
Anticancer Res; 2005; 25(3A):1523-30. PubMed ID: 16033054
[TBL] [Abstract][Full Text] [Related]
3. Chemoradiation of unresectable pancreatic carcinoma: impact of pretreatment hemoglobin level on patterns of failure.
Morganti AG; Forni F; Macchia G; Valentini V; Smaniotto D; Trodella L; Balducci M; Cellini N
Strahlenther Onkol; 2003 Feb; 179(2):87-92. PubMed ID: 12590318
[TBL] [Abstract][Full Text] [Related]
4. Topical issues in the treatment of rectal cancer: economic and organizational aspects of concomitant radiochemotherapy.
Valentini V; Turriziani A; Cianciulli M; Niespolo RM; Fares MC; Morganti AG
Rays; 1999; 24(3):453-9. PubMed ID: 10605306
[TBL] [Abstract][Full Text] [Related]
5. Carcinoma of the pancreatic head area. Therapy: concomitant radiochemotherapy.
Cellini N; Valentini V; Trodella L; Balducci M; Morganti AG; Turriziani A
Rays; 1995; 20(3):350-9. PubMed ID: 8559976
[TBL] [Abstract][Full Text] [Related]
6. 5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: Phase I-II dose-escalation study.
Morganti AG; Valentini V; Macchia G; Mattiucci GC; Costamagna G; Deodato F; Smaniotto D; Luzi S; Balducci M; Barbi S; Perri V; Trodella L; Cellini N
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1454-60. PubMed ID: 15275732
[TBL] [Abstract][Full Text] [Related]
7. Biliary stents in malignant obstructive jaundice due to pancreatic carcinoma: a cost-effectiveness analysis.
Arguedas MR; Heudebert GH; Stinnett AA; Wilcox CM
Am J Gastroenterol; 2002 Apr; 97(4):898-904. PubMed ID: 12003425
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
Keene KS; Rich TA; Penberthy DR; Shepard RC; Adams R; Jones RS
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):97-103. PubMed ID: 15850908
[TBL] [Abstract][Full Text] [Related]
9. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
[TBL] [Abstract][Full Text] [Related]
11. Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.
Miller RC; Iott MJ; Corsini MM
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):364-8. PubMed ID: 19735864
[TBL] [Abstract][Full Text] [Related]
12. Asymptomatic pancreatic cystic neoplasm: a cost-effectiveness analysis of different strategies of management.
Das A; Ngamruengphong S; Nagendra S; Chak A
Gastrointest Endosc; 2009 Oct; 70(4):690-699.e6. PubMed ID: 19647240
[TBL] [Abstract][Full Text] [Related]
13. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin.
Kornek GV; Schratter-Sehn A; Marczell A; Depisch D; Karner J; Krauss G; Haider K; Kwasny W; Locker G; Scheithauer W
Br J Cancer; 2000 Jan; 82(1):98-103. PubMed ID: 10638974
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
Hillner BE; Schrag D; Sargent DJ; Fuchs CS; Goldberg RM
Cancer; 2005 Nov; 104(9):1871-84. PubMed ID: 16177989
[TBL] [Abstract][Full Text] [Related]
15. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy.
Ess SM; Szucs TD
Ital Heart J; 2001 Mar; 2(3):181-8. PubMed ID: 11305529
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness of epilepsy surgery in a cohort of patients with medically intractable partial epilepsy--preliminary results].
Picot MC; Neveu D; Kahane P; Crespel A; Gélisse P; Hirsch E; Derambure P; Dupont S; Landré E; Chassoux F; Valton L; Vignal JP; Marchal C; Rougier A; Lamy C; Semah F; Biraben A; Arzimanoglou A; Petit J; Thomas P; Dujols P; Ryvlin P
Rev Neurol (Paris); 2004 Jun; 160 Spec No 1():5S354-67. PubMed ID: 15331984
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: implications from five randomized trials.
Rose PG; Lappas PT
Gynecol Oncol; 2000 Jul; 78(1):3-6. PubMed ID: 10873400
[TBL] [Abstract][Full Text] [Related]
18. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?
Sheerin IG; Green FT; Sellman JD
Drug Alcohol Rev; 2004 Sep; 23(3):261-72. PubMed ID: 15370005
[TBL] [Abstract][Full Text] [Related]
19. Radiation therapy with and without chemotherapy in the treatment of localized unresectable pancreatic carcinoma. A retrospective analysis.
Jones KG; Lindberg RD; Epremian B; Jose B; Spanos WJ
J Ky Med Assoc; 1987 Jun; 85(6):305-9. PubMed ID: 3611960
[No Abstract] [Full Text] [Related]
20. Functional evaluation of the human pancreas before and in the early period after hyperfractionated accelerated radiochemotherapy.
Horst E; Seidel M; Micke O; Rübe C; Schäfer U; Willich N
Front Radiat Ther Oncol; 2002; 37():17-25. PubMed ID: 11764659
[No Abstract] [Full Text] [Related]
[Next] [New Search]
